Published in Dig Dis Sci on September 01, 1993
Helicobacter pylori. Clin Microbiol Rev (1997) 9.22
Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut (1998) 1.32
Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut (1995) 1.19
One-day high-dose combined therapy of Helicobacter pylori infection. Dig Dis Sci (1997) 0.79
Efficacy of one-day quadruple therapy for H pylori infection in Chinese patients. World J Gastroenterol (2006) 0.79
Is short-term therapy really sufficient to eradicate Helicobacter pylori infection? J Zhejiang Univ Sci B (2010) 0.75
Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial. World J Gastroenterol (2006) 0.75
One-day combined therapy of children with Helicobacter pylori-associated peptic disease. Dig Dis Sci (1996) 0.75
Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet (1983) 23.90
Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet (1990) 9.49
Campylobacter-like organisms in the stomach of patients and healthy individuals. Lancet (1984) 7.45
Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet (1989) 6.58
The histological diagnosis of chronic gastritis in fibreoptic gastroscope biopsy specimens. J Clin Pathol (1972) 6.07
One week eradication regimen for Helicobacter pylori. Lancet (1991) 4.50
Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol (1988) 2.52
Campylobacter pylori: its link to gastritis and peptic ulcer disease. Rev Infect Dis (1990) 2.18
Effect of age on the frequency of active Campylobacter pylori infection diagnosed by the [13C]urea breath test in normal subjects and patients with peptic ulcer disease. J Infect Dis (1988) 2.01
Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust (1989) 1.73
Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother (1988) 1.57
Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with amoxycillin. Am J Gastroenterol (1988) 1.24
Helicobacter pylori therapy: effect on peptic ulcer disease. J Gastroenterol Hepatol (1991) 1.15
Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut (1990) 1.15
Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scand J Gastroenterol Suppl (1989) 1.03
Monotherapy or polychemotherapy in the treatment of Campylobacter pylori-related gastroduodenal disease. Scand J Gastroenterol Suppl (1988) 1.01
Helicobacter pylori: bridging the credibility gap. Gut (1990) 0.97
Congenital diaphragmatic hernia in the newborn. Outcome in 59 consecutive cases over a ten year period (1980-1989). Ir J Med Sci (1992) 0.94
Physicochemical properties of amphoteric beta-lactam antibiotics I: Stability, solubility, and dissolution behavior of amino penicillins as a function of pH. J Pharm Sci (1978) 0.94
Campylobacter pylori--therapy review. Scand J Gastroenterol Suppl (1989) 0.85
Bismuth/ofloxacin combination for duodenal ulcer. Lancet (1987) 0.82
Clinical presentation and natural history of chronic persistent hepatitis. A multicentre retrospective study on 1197 cases. Ital J Gastroenterol (1992) 0.78
Functional gastroduodenal disorders. Gut (1999) 3.74
Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut (2008) 3.52
Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology (1996) 3.22
Persistent hepatitis C viraemia without liver disease. Lancet (1993) 3.14
Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol (2000) 3.08
Chronic idiopathic intestinal pseudo-obstruction: clinical and intestinal manometric findings. Gut (1987) 2.46
Diabetes is associated with longer survival rates in patients with malignant tumors. Arch Intern Med (2000) 2.40
Manometric evaluation of functional upper gut symptoms. Gastroenterology (1985) 2.38
Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med (1997) 2.33
Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther (2003) 2.28
Endoscopic demonstration of loss of duodenal folds in the diagnosis of celiac disease. N Engl J Med (1988) 2.27
Definition and investigation of dyspepsia. Consensus of an international ad hoc working party. Dig Dis Sci (1989) 2.23
Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol (2013) 2.21
Role of serum pancreatic enzyme assays in diagnosis of pancreatic disease. Dig Dis Sci (1989) 2.17
Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction. Gut (2004) 2.04
Diagnosis and treatment of chronic constipation--a European perspective. Neurogastroenterol Motil (2011) 1.99
The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab (1993) 1.94
Enzymatic determination of cholesterol in bile. Clin Chim Acta (1975) 1.88
Gastro-oesophageal reflux and interstitial lung disease. Dig Liver Dis (2006) 1.85
Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther (2009) 1.83
Prevalence of spontaneous hepatofugal portal flow in liver cirrhosis. Clinical and endoscopic correlation in 228 patients. Gastroenterology (1991) 1.82
Gallstone recurrence after successful oral bile acid treatment. A 12-year follow-up study and evaluation of long-term postdissolution treatment. Gastroenterology (1989) 1.81
Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther (2012) 1.79
Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Aliment Pharmacol Ther (1999) 1.76
Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res (2004) 1.76
Effect of meal on portal hemodynamics in healthy humans and in patients with chronic liver disease. Hepatology (1989) 1.70
Reversal of fundic atrophy after eradication of Helicobacter pylori. Am J Gastroenterol (1998) 1.61
Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther (1994) 1.59
JC virus infects the enteric glia of patients with chronic idiopathic intestinal pseudo-obstruction. Gut (2008) 1.59
Endoscopic markers in adult coeliac disease. Dig Liver Dis (2002) 1.58
Evaluation of GERD symptoms during therapy. Part I. Development of the new GERD questionnaire ReQuest. Digestion (2004) 1.57
A role for inflammation in irritable bowel syndrome? Gut (2002) 1.57
A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology (1994) 1.53
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC). Ann Oncol (2003) 1.52
The quality of life in patients with chronic pancreatitis evaluated using the SF-12 questionnaire: a comparative study with the SF-36 questionnaire. Dig Liver Dis (2005) 1.52
Prospective screening of dyspeptic patients by Helicobacter pylori serology: a safe policy? The Italian Helicobacter pylori Study Group. Endoscopy (1997) 1.52
New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther (2004) 1.45
Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol (2005) 1.41
Diabetic retinopathy in chronic pancreatitis. Gastroenterology (1990) 1.41
Stress-induced gastroduodenal motor disturbances in humans: possible humoral mechanisms. Gastroenterology (1983) 1.40
Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. Gastroenterology (1992) 1.40
Evaluation of two therapeutic regimens for the treatment of Helicobacter pylori infection. Ital J Gastroenterol (1994) 1.38
Fasting and postprandial gastrointestinal motility in ulcer and non-ulcer dyspepsia. Gut (1992) 1.38
Lipid, lipoprotein, and apolipoprotein assessment during an 8-wk very-low-calorie diet. Am J Clin Nutr (1992) 1.37
Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology (1997) 1.36
Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterol Motil (2007) 1.35
Assessment of portal hypertension by endoscopic ultrasonography. Gastrointest Endosc (1990) 1.34
Familial syndrome of midsystolic click and late systolic murmur. Br Heart J (1973) 1.32
New insights into human enteric neuropathies. Neurogastroenterol Motil (2004) 1.31
Acid gastroesophageal reflux and symptom occurrence. Analysis of some factors influencing their association. Dig Dis Sci (1989) 1.30
Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab (1989) 1.29
The medical treatment of cholesterol gallstones: experience with chenodeoxycholic acid. Digestion (1976) 1.29
Review article: the pharmacological treatment of acute colonic pseudo-obstruction. Aliment Pharmacol Ther (2001) 1.24
Review article: molecular, pathological and therapeutic features of human enteric neuropathies. Aliment Pharmacol Ther (2008) 1.24
Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil (2006) 1.23
Prevalence of peptic ulcer in Helicobacter pylori positive blood donors. Gut (1994) 1.22
Liver cirrhosis: changes of Doppler waveform of hepatic veins. Radiology (1991) 1.20
Apoptotic cell death of human interstitial cells of Cajal. Neurogastroenterol Motil (2008) 1.20
Omeprazole, Helicobacter pylori, gastritis, and duodenal ulcer. Lancet (1989) 1.19
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer (2005) 1.18
Gastrointestinal motility disturbances in patients with orthostatic hypotension. Gastroenterology (1985) 1.16
Relapsing ulcerative colitis after spinal cord stimulation: a case of intestinal neurogenic inflammation? Gastroenterology (1999) 1.16
Diagnostic value of serum primary bile acids in detecting bile acid malabsorption. Gut (1982) 1.16
Can antigliadin antibody detect symptomless coeliac disease in children with short stature? Lancet (1985) 1.14
Fat-induced ileal brake in humans: a dose-dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology (1993) 1.13
Value of endoscopic ultrasonography in the management of portal hypertension. Endoscopy (1992) 1.12
Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer (2003) 1.11